- Profile
- prev
- next
General
-
Headquarters
San Diego, California 92121, United States
-
Founders & Team
Osman Kibar, Cevdet Samikoglu, Yusuf Yazici, Arman Oruc, Neil Bair, Blake Mobley, Erich Horsley, Philippe Marchand
-
Year Founded
2008
-
Number of employees
200
-
Company type
Private company
-
Funding stage
Series C
-
Total funding ($M)
658
-
Investors
Polar Light Ventures, Vickers Ventures Partners, Starling Group, Vickers Venture Partners
Technical Details
-
Aging Target
Altered intercellular communication, Cell Loss
-
Disease indication
cancer, osteoarthritis, androgenic alopecia
-
Product modality
small molecule drugs
-
Clinical stage
Phase 3 Trials
-
Product names
Lorecivivint
About
Biosplice’s mission is to restore health by delivering first-in-class therapies that harness alternative splicing.
Our scientific platform is based on biological discoveries that govern tissue specialization and enable us to selectively eliminate harmful proteins using small molecules. From our foundational discoveries in Wnt pathway modulation to unlocking the broad therapeutic potential of the CLK/DYRK target class, our focus is on the realization of new, potentially curative therapies for patients by selectively reprogramming cellular behavior.